AbTis has developed a proprietary technology that enhances the safety and efficacy of antibody-drug conjugates without the need for genetic engineering. Their technology can be applied to native antibodies, commercial antibodies, and novel antibodies under development. By providing access to antibody-drug conjugates, AbTis aims to improve medical treatments.